Immunotherapies with mAbs specific to CD19, CD20, CD22, CD38, as well as chimeric antigen receptor (CAR)-modified T cell therapy, have recently revolutionized the treatment of hematological malignancies. This evidence concerns the gene CD38 and hematologic disorder.